Urgent Nephrology Referral and Dialysis Preparation Required
This patient has progressed to kidney failure (stage 5 CKD/ESKD) and requires immediate nephrology consultation for dialysis initiation, as the eGFR <15 mL/min with markedly elevated BUN indicates uremic syndrome risk. 1
Critical Assessment
Your patient's laboratory values indicate:
- eGFR <15 mL/min = Stage 5 CKD (kidney failure), NOT stage 3
- BUN 120 mg/dL with creatinine 4.26 mg/dL yields a BUN/Cr ratio of ~28, suggesting intrinsic kidney disease rather than prerenal azotemia
- This represents either acute-on-chronic kidney disease or unrecognized progression from previously documented stage 3 CKD
Immediate Management Steps
1. Urgent Nephrology Referral (Within 72 Hours)
The KDIGO 2024 guidelines explicitly recommend nephrology consultation for eGFR <30 mL/min per 1.73 m² 1. Your patient is well below this threshold at <15 mL/min and requires:
- Assessment for dialysis initiation
- Evaluation for kidney transplant candidacy
- Vascular access planning (arteriovenous fistula creation takes 3-6 months to mature)
2. Assess for Uremic Symptoms
Examine for signs requiring urgent dialysis:
- Pericarditis (friction rub, chest pain)
- Encephalopathy (confusion, asterixis, seizures)
- Severe nausea/vomiting with malnutrition
- Volume overload refractory to diuretics
- Metabolic acidosis (pH <7.2)
- Hyperkalemia >6.5 mEq/L or refractory to medical management
- BUN >100 mg/dL with symptoms (your patient meets this criterion)
3. Medication Review and Adjustment
RAS Inhibitors (ACEi/ARB): According to KDIGO 2024, consider reducing dose or discontinuing ACEi/ARB at eGFR <15 mL/min to reduce uremic symptoms while treating kidney failure 1. However, if already on these medications and tolerating well without hyperkalemia or symptomatic hypotension, continuation is reasonable until dialysis initiation.
SGLT2 Inhibitors: If the patient is on an SGLT2i, it is reasonable to continue even with eGFR <20 mL/min until dialysis is initiated 1. However, do not initiate SGLT2i at this stage.
Avoid nephrotoxins:
- NSAIDs
- Aminoglycosides
- IV contrast (use only if absolutely necessary with hydration)
- Renally-dosed all medications
4. Laboratory Monitoring
Check immediately:
- Potassium (hyperkalemia risk with eGFR <15)
- Bicarbonate (metabolic acidosis common)
- Calcium, phosphorus, PTH (mineral bone disease)
- Hemoglobin (anemia of CKD)
- Albumin (nutritional status)
- Urinalysis with albumin-to-creatinine ratio (if not recently done)
5. Supportive Management Pending Nephrology Evaluation
- Hyperkalemia: Dietary potassium restriction (<2g/day), consider potassium binders if K+ >5.5 mEq/L
- Metabolic acidosis: Sodium bicarbonate if HCO3 <22 mEq/L
- Anemia: Likely needs erythropoiesis-stimulating agents and iron supplementation
- Hyperphosphatemia: Phosphate binders with meals, dietary restriction
- Volume management: Loop diuretics if still making urine; fluid restriction if anuric
- Dietary protein restriction: 0.6-0.8 g/kg/day to reduce uremic toxin accumulation 2
Common Pitfalls to Avoid
- Delaying nephrology referral: With eGFR <15, this patient needs subspecialty care immediately, not "routine" outpatient follow-up 3
- Continuing nephrotoxic medications: Review entire medication list for renal dosing
- Missing reversible causes: Rule out obstruction (bladder scan, renal ultrasound), volume depletion, or medication-induced AKI superimposed on CKD
- Inadequate patient education: Discuss dialysis modalities (hemodialysis vs peritoneal dialysis) and transplant options early 4
Prognosis Context
The markedly elevated BUN (120 mg/dL) with this degree of renal dysfunction is associated with poor clinical outcomes including increased mortality and hospital readmission risk 5. This underscores the urgency of nephrology involvement and potential dialysis initiation.